NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
Live webcasts and archived replays of NewAmsterdam’s September 9 and 10 fireside chats will be posted on its investor relations site.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NewAmsterdam Pharma (NAMS) will participate in two investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, and the Cantor Global Healthcare Conference 2026 in New York on September 10.
Company executives, including CEO Michael Davidson, CFO Ian Somaiya, and Head of Investor Relations Matthew Philippe, will join fireside chats at 3:45 p.m. ET and 2:45 p.m. ET, respectively. Live webcasts and archived replays of both presentations will be accessible via the investor relations section of NewAmsterdam Pharma’s website.
Details
News Market Reaction – NAMS
On Sep 2, the day this news came out, NAMS closed 2.69% above the previous close. Our momentum scanner recorded 2 alerts for this stock that day. Relative volume reached 1.7x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
- Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 3:45 p.m. ET on Wednesday, September 9.
- Cantor Global Healthcare Conference 2026 in New York, NY on Thursday, September 10, 2026. Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:45 p.m. ET on Thursday, September 10.
Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.